No Data
Express News | Ionis Expands Partnership With Sobi to Include Olezarsen Commercialization Outside the U.S.
Express News | Ionis Pharmaceuticals Announced That It Has Entered Into A License Agreement Under Which Sobi Receives Exclusive Rights In Countries Outside The U.S., Canada And China To Commercialize Olezarsen As A Potential Treatment For Familial Chylomicronemia...
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Ionis Pharmaceuticals Price Target Cut to $45.00/Share From $47.00 by JP Morgan
